TR199902934T2 - S-Omeprazolün yeni yapisi. - Google Patents

S-Omeprazolün yeni yapisi.

Info

Publication number
TR199902934T2
TR199902934T2 TR1999/02934T TR9902934T TR199902934T2 TR 199902934 T2 TR199902934 T2 TR 199902934T2 TR 1999/02934 T TR1999/02934 T TR 1999/02934T TR 9902934 T TR9902934 T TR 9902934T TR 199902934 T2 TR199902934 T2 TR 199902934T2
Authority
TR
Turkey
Prior art keywords
omeprazole
refers
new structure
enantiomer
methoxy
Prior art date
Application number
TR1999/02934T
Other languages
English (en)
Inventor
Cotton Hanna
Kronstr�m Anders
Mattson Anders
M�ller Eva
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20407186&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR199902934(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Publication of TR199902934T2 publication Critical patent/TR199902934T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Abstract

Bu bulus, 5-metoksi-2-[[(4-metoksi-3, 5-dimetil-2-pridinil)-metil]sülfinil]-1H-benzimidazol'ün (-) enantiomeri, yani S-omeprazol'ün yeni yapisina iliskindir. Daha özele inilirse, omeprazol trihidrat'in S-enantiomerinin magnezyum tuzunun yeni bir yapisina deginir. Bu bulus ayni zamanda, böyle bir yapiya sahip magnezyum tuzu ve bu tuzu içeren ilaç bilesimleri hazirlamak için kullanilan proseslere deginir. Bunun da ötesinde bulus, prosesteki ara ürünlere de deginir.
TR1999/02934T 1997-05-30 1998-05-25 S-Omeprazolün yeni yapisi. TR199902934T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9702065A SE510650C2 (sv) 1997-05-30 1997-05-30 Ny förening

Publications (1)

Publication Number Publication Date
TR199902934T2 true TR199902934T2 (tr) 2000-04-21

Family

ID=20407186

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/02934T TR199902934T2 (tr) 1997-05-30 1998-05-25 S-Omeprazolün yeni yapisi.

Country Status (44)

Country Link
US (6) US6369085B1 (tr)
EP (2) EP1273581B1 (tr)
JP (2) JP4002303B2 (tr)
KR (2) KR100540720B1 (tr)
CN (1) CN1161351C (tr)
AR (2) AR012717A1 (tr)
AT (2) ATE239011T1 (tr)
AU (1) AU722839B2 (tr)
BR (1) BR9809509A (tr)
CA (2) CA2290963C (tr)
CY (1) CY2012029I2 (tr)
CZ (1) CZ297585B6 (tr)
DE (3) DE69829511T2 (tr)
DK (2) DK0984957T3 (tr)
DZ (1) DZ2495A1 (tr)
EE (1) EE03875B1 (tr)
EG (1) EG24291A (tr)
ES (2) ES2236407T3 (tr)
HK (2) HK1025962A1 (tr)
HR (1) HRP980263B1 (tr)
HU (1) HU225987B1 (tr)
ID (1) ID29306A (tr)
IL (1) IL132947A0 (tr)
IS (2) IS2142B (tr)
LU (2) LU91871I2 (tr)
MA (1) MA26500A1 (tr)
ME (3) MEP24908A (tr)
MY (2) MY120745A (tr)
NO (3) NO317518B1 (tr)
NZ (1) NZ500991A (tr)
PL (1) PL193546B1 (tr)
PT (2) PT984957E (tr)
RS (2) RS50067B (tr)
RU (1) RU2184115C2 (tr)
SA (2) SA05260296B1 (tr)
SE (1) SE510650C2 (tr)
SI (2) SI1273581T1 (tr)
SK (2) SK285137B6 (tr)
TN (1) TNSN98074A1 (tr)
TR (1) TR199902934T2 (tr)
TW (1) TW538040B (tr)
UA (1) UA60334C2 (tr)
WO (1) WO1998054171A1 (tr)
ZA (1) ZA984179B (tr)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
PT909323E (pt) 1996-01-04 2007-06-04 Novartis Vaccines & Diagnostic ''bacterioferritina de helicobacter pilori''
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
SE9900274D0 (sv) * 1999-01-28 1999-01-28 Astra Ab New compound
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6369087B1 (en) * 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
CA2474246C (en) 2002-03-05 2010-06-29 Astrazeneca Ab Alkylammonium salts of omeprazole and esomeprazole
WO2003089408A2 (en) * 2002-04-22 2003-10-30 Sun Pharmaceutical Industries Limited Optically active substituted pyridinylmethyl-sulphinyl-benzimidazole and salts
AU2003247729B2 (en) * 2002-06-27 2009-10-08 Dr. Reddy's Laboratories Limited A process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof
EP1515963B1 (en) 2002-06-27 2007-02-14 Dr. Reddy's Laboratories Ltd. A process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
AU2003262992A1 (en) * 2002-08-30 2004-03-19 Reddy's Laboratories Limited Amorphous hydrates of esomeprazole magnesium and process for the preparation thereof
CA2771725C (en) * 2002-10-16 2015-08-18 Takeda Pharmaceutical Company Limited Solid preparation comprising a non-toxic base and a proton pump inhibitor
EP1556043A1 (en) * 2002-10-22 2005-07-27 Ranbaxy Laboratories, Ltd. Amorphous form of esomeprazole salts
WO2004046134A2 (en) * 2002-11-18 2004-06-03 Dr. Reddy's Laboratories Limited Crystalline form ii of esomeprazole magnesium trihydrate and process for its preparation
US20060094762A1 (en) * 2003-01-07 2006-05-04 Yatendra Kumar Magnesium salt of imidazole derivative
AU2003238671A1 (en) * 2003-04-10 2004-11-01 Hetero Drugs Limitd Novel crystalline forms of s-omeprazole magnesium
CN1842525A (zh) 2003-05-05 2006-10-04 兰贝克赛实验室有限公司 苯并咪唑衍生物的钡盐
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CN100457104C (zh) * 2003-07-23 2009-02-04 尼科梅德有限责任公司 质子泵抑制剂的碱性盐
ATE386522T1 (de) * 2003-07-23 2008-03-15 Nycomed Gmbh Alkalisalze von protonenpumpen-hemmern
SE0302381D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts I
SE0302382D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts II
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
BRPI0507784A (pt) * 2004-02-18 2007-07-17 Allergan Inc métodos e composições para a administração de pró-fármacos de inibidores da bomba de prótons
WO2005082338A2 (en) * 2004-02-18 2005-09-09 Allergan, Inc. Prodrugs for the intravenous administration of proton pump inhibitors
AU2005249367A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050267157A1 (en) * 2004-05-28 2005-12-01 David White Magnesium-S-omeprazole
US20050267159A1 (en) * 2004-05-28 2005-12-01 Aaipharma, Inc. Magnesium complexes of S-omeprazole
JP5563735B2 (ja) 2004-06-16 2014-07-30 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド Ｐｐｉ多回剤形
JP5457632B2 (ja) * 2004-06-24 2014-04-02 アストラゼネカ・アクチエボラーグ エソメプラゾールのナトリウム塩の製造に使用するための結晶の改変型の作成方法
ES2246149B1 (es) 2004-07-02 2007-06-01 Esteve Quimica, S.A. Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
WO2006073779A1 (en) * 2004-12-30 2006-07-13 Transform Phamaceuticals, Inc. Novel omeprazole forms and related methods
ES2259269B1 (es) 2005-03-03 2007-11-01 Esteve Quimica, S.A. Procedimiento para la preparacion de derivados de 2-(2-piridilmetilsulfinil)-bencimidazol opticamente activos.
US20060210637A1 (en) * 2005-03-17 2006-09-21 Qpharma, Llc Stable tablet dosage forms of proton pump inhibitors
RU2007145207A (ru) * 2005-05-06 2009-06-20 Гленмарк Фармасьютикалз Лимитед (In) Стронциваемая соль эзомепразола, способ ее получения и содержащее ее фармацевтические композиции
EP1891043A1 (en) * 2005-06-15 2008-02-27 Hetero Drugs Limited Amorphous esomeprazole hydrate
WO2007008588A2 (en) * 2005-07-07 2007-01-18 Dr. Reddy's Laboratories Ltd. Omeprazole form b
KR100641534B1 (ko) 2005-07-28 2006-11-01 한미약품 주식회사 에스오메프라졸 및 그의 염의 제조방법
US20070026071A1 (en) * 2005-07-28 2007-02-01 Qpharma, Llc Magnesium salt proton pump inhibitor dosage forms
WO2007031845A2 (en) * 2005-09-14 2007-03-22 Glenmark Pharmaceuticals Limited Polymorphic forms of (s)-omeprazole magnesium salts and processes for their preparation
JP2009511481A (ja) * 2005-10-06 2009-03-19 オースペックス・ファーマシューティカルズ・インコーポレイテッド 増強された治療特性を持つ、胃Ｈ＋，Ｋ＋−ＡＴＰａｓｅの重水素化阻害剤
AU2006306906B2 (en) * 2005-10-26 2010-02-04 Hanmi Science Co., Ltd. S-omeprazole strontium or hydrate thereof, method for preparing same, and pharmaceutical composition comprising same
US7576219B2 (en) 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
US7553857B2 (en) * 2005-12-23 2009-06-30 Lek Pharmaceuticals D.D. S-omeprazole magnesium
CN100384839C (zh) * 2006-02-17 2008-04-30 中国科学院上海有机化学研究所 [(取代的吡啶基)甲基]亚磺酰基-1h-苯并咪唑类化合物及其对映体的锌盐的制备方法
US7579476B2 (en) * 2006-02-24 2009-08-25 Praktikatalyst Pharma, Llc Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals
US8063074B2 (en) 2006-05-04 2011-11-22 Dr. Reddy's Laboratories Limited Polymorphic forms of esomeprazole sodium
EP2040710A2 (en) * 2006-06-21 2009-04-01 Glenmark Pharmaceuticals Limited Novel polymorph of esomeprazole potassium and process for its preparation
GB2444593B (en) 2006-10-05 2010-06-09 Santarus Inc Novel formulations for immediate release of proton pump inhibitors and methods of using these formulations
CA2667682A1 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
EP1947099A1 (en) * 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Process for solvent removal from omeprazole salts
EA200900985A1 (ru) 2007-01-31 2009-12-30 Крка, Товарна Здравил, Д. Д., Ново Место Способ получения оптически чистого омепразола
CA2889878A1 (en) * 2007-02-21 2008-08-28 Cipla Limited Process for the preparation of esomeprazole magnesium dihydrate
KR101303813B1 (ko) * 2007-04-16 2013-09-04 에스케이케미칼주식회사 라세믹 오메프라졸로부터 에스오메프라졸의 개선된제조방법
EP2000468A1 (en) 2007-05-09 2008-12-10 Dr. Reddy's Laboratories Ltd. Esomeprazole salts and processes for preparation thereof
US8492551B2 (en) * 2007-06-07 2013-07-23 Aurobindo Pharma. Ltd. Process for preparing an optically active proton pump inhibitor
FR2920428B1 (fr) * 2007-08-29 2012-06-15 Univ Rouen Procede de dedoublement de sels de l'omeprazole
US8106210B2 (en) * 2007-10-08 2012-01-31 Hetero Drugs Limited Polymorphs of esomeprazole salts
BRPI0818286A2 (pt) 2007-10-12 2020-08-11 Takeda Pharmaceuticals North America, Inc. métodos de tratamento de distúrbios gastrointestinais independente da ingestão de alimento.
WO2009074997A2 (en) * 2007-12-10 2009-06-18 Lee Pharma Ltd. A novel process for the preparation of crystalline magnesium salt of (s)-omeprazole di hydrate
EP2240496A4 (en) * 2008-02-01 2011-05-11 Reddys Lab Ltd Dr PREPARATION OF MAGNESIUM OF ESOMEPRAZOLE AND ITS HYDRATES
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
US20090280175A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Proton Pump Inhibitor Tablets
EP2143722A1 (en) 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium
EP2147918A1 (en) * 2008-07-21 2010-01-27 LEK Pharmaceuticals D.D. Process for the preparation of S-omeprazole magnesium in a stable form
MX2011002515A (es) 2008-09-09 2011-04-07 Astrazeneca Ab Metodo de administracion de una composicion farmaceutica a un paciente que lo necesita.
CN101391993B (zh) * 2008-10-28 2012-07-04 安徽美诺华药物化学有限公司 通过与(s)-(-)-1,1'-联萘-2,2'-二酚形成包合配合物制备s-奥美拉唑及其盐的方法
WO2010097583A1 (en) 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
US20100267959A1 (en) * 2009-04-15 2010-10-21 Glenmark Generics Limited Process for the preparation of esomeprazole magnesium dihydrate
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
WO2010150276A2 (en) * 2009-06-02 2010-12-29 Sun Pharmaceutical Industries Limited Process for preparing sulphoxide compounds
CN102638978A (zh) * 2009-06-25 2012-08-15 波曾公司 用于治疗需要阿司匹林治疗之患者的方法
JP2012531409A (ja) 2009-06-25 2012-12-10 アストラゼネカ・アクチエボラーグ Ｎｓａｉｄ関連潰瘍を発症するリスクがある患者の処置方法
WO2011012957A1 (en) * 2009-07-29 2011-02-03 Orchid Chemicals & Pharmaceuticals Ltd An improved process for the preparation of esomeprazole magnesium dihydrate
WO2011058569A1 (en) 2009-11-12 2011-05-19 Hetero Research Foundation Process for the resolution of omeprazole
WO2011071982A2 (en) 2009-12-08 2011-06-16 Codexis, Inc. Synthesis of prazole compounds
US20110207779A1 (en) * 2010-02-25 2011-08-25 Glenmark Generics Ltd Process for the preparation of esomeprazole magnesium
FR2959509B1 (fr) 2010-05-03 2012-07-13 Prod Chim Auxiliaires Et De Synthese Phase precurseur et son utilisation pour preparer le sel de magnesium tetrahydrate d'un enantiomere d'omeprazole
CN102241668B (zh) * 2010-05-11 2015-11-25 中国科学院成都有机化学有限公司 S-奥美拉唑盐
DK2649187T3 (da) 2010-12-08 2018-01-29 Codexis Inc Biokatalysatorer og fremgangsmåder til syntesen af armodafinil
CN102757421A (zh) * 2011-04-29 2012-10-31 江苏正大天晴药业股份有限公司 埃索美拉唑的纯化方法
CN102911158B (zh) * 2011-07-31 2015-07-22 连云港润众制药有限公司 埃索美拉唑镁的晶型
CN102936238B (zh) * 2011-11-25 2015-02-18 成都自豪药业有限公司 S-奥美拉唑镁盐的晶型及其制备方法
WO2013088272A1 (en) * 2011-12-14 2013-06-20 Wockhardt Limited Pharmaceutical composition comprising esomeprazole magnesium dihydrate
CN104519888A (zh) 2011-12-28 2015-04-15 波曾公司 用于递送奥美拉唑和乙酰水杨酸的改良组合物和方法
CN102584792B (zh) * 2012-01-06 2014-06-11 南京优科生物医药研究有限公司 制备高纯度的埃索美拉唑盐的方法
CN102993184A (zh) * 2013-01-08 2013-03-27 湖南方盛制药股份有限公司 一种埃索美拉唑及其镁盐三水合物的制备方法
CN104250243B (zh) * 2013-06-27 2016-12-28 四川国为制药有限公司 一种埃索美拉唑镁二水合物a晶型的制备方法
CN103570686B (zh) * 2013-10-14 2015-04-01 哈药集团技术中心 一种埃索美拉唑钠的合成及精制工艺
CN104725357A (zh) * 2013-12-24 2015-06-24 苏州联友制药技术有限公司 一种埃索美拉唑镁二水合物晶型b的制备方法
FR3018812A1 (fr) 2014-03-21 2015-09-25 Minakem Nouvelle phase intermediaire de la forme a du sel de magnesium dihydrate d'un enantiomere de l'omeprazole
CN104447699A (zh) * 2014-12-10 2015-03-25 哈药集团技术中心 一种埃索美拉唑镁三水合物的制备方法
CN105111188B (zh) * 2015-08-19 2018-01-19 扬子江药业集团有限公司 一种埃索美拉唑镁三水合物晶型的制备方法
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
CN106397402B (zh) * 2016-08-30 2019-05-03 山东罗欣药业集团股份有限公司 一种埃索美拉唑镁晶型化合物及其制备方法
KR102080023B1 (ko) 2018-01-29 2020-02-21 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
KR102006777B1 (ko) 2018-01-29 2019-10-08 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제
KR102432084B1 (ko) 2021-11-16 2022-08-12 알리코제약(주) S-오메프라졸을 함유하는 안정성이 개선되고 소형화된 정제
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
US5244891A (en) 1985-08-05 1993-09-14 Bristol-Myers Squibb Company Injectable compositions of cefepime dihydrochloride hydrate
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5204118A (en) 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
US5360582A (en) 1991-07-15 1994-11-01 Minnesota Mining And Manufacturing Company Nonlinear optical materials containing polar disulfone-functionalized molecules
US5877192A (en) 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
FR2719045B1 (fr) * 1994-04-20 1996-05-31 Rhone Poulenc Chimie Procédé de préparation d'acide L-aspartique à partir d'aspartate d'ammonium.
AU695966B2 (en) 1994-07-08 1998-08-27 Astrazeneca Ab Multiple unit tableted dosage form I
FR2722191B1 (fr) 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
DK0792879T3 (da) 1994-11-14 2001-03-26 Daiichi Seiyaku Co Fremgangsmåde til fremstilling af 3-[2-[4-(3-chlor-2-methylphenyl)-1-piperzinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)
GB9423970D0 (en) 1994-11-28 1995-01-11 Astra Ab Oxidation
SE9500422D0 (sv) 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
CN1042423C (zh) 1995-05-25 1999-03-10 常州市第四制药厂 奥美拉唑盐水合物及其制备方法
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE9600072D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
US6747155B2 (en) * 1997-05-30 2004-06-08 Astrazeneca Ab Process
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
AR057181A1 (es) 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion

Also Published As

Publication number Publication date
DE69814069D1 (de) 2003-06-05
KR20050042827A (ko) 2005-05-10
EP0984957B1 (en) 2003-05-02
US6677455B2 (en) 2004-01-13
ZA984179B (en) 1998-11-30
UA60334C2 (uk) 2003-10-15
AU7793598A (en) 1998-12-30
ES2236407T3 (es) 2005-07-16
HK1051681A1 (en) 2003-08-15
HUP0001849A2 (hu) 2002-05-29
DZ2495A1 (fr) 2003-01-25
KR100540720B1 (ko) 2006-01-12
NZ500991A (en) 2001-05-25
SE9702065D0 (sv) 1997-05-30
HUP0001849A3 (en) 2003-02-28
DK1273581T3 (da) 2005-06-06
CY2012029I1 (el) 2015-08-05
PL193546B1 (pl) 2007-02-28
TW538040B (en) 2003-06-21
IS2142B (is) 2006-09-15
MY120745A (en) 2005-11-30
WO1998054171A8 (en) 1999-12-23
CA2521391C (en) 2009-09-29
SE510650C2 (sv) 1999-06-14
IS8368A (is) 2006-03-22
MEP24908A (en) 2010-10-10
ES2195345T7 (es) 2014-01-15
NO995852D0 (no) 1999-11-29
HK1025962A1 (en) 2000-12-01
ME00198B (me) 2011-02-10
DE69814069T2 (de) 2004-04-01
PT984957E (pt) 2003-07-31
NO995852L (no) 2000-01-31
EP1273581B1 (en) 2005-03-23
DK0984957T3 (da) 2003-06-30
US6369085B1 (en) 2002-04-09
EE03875B1 (et) 2002-10-15
RS50005B (sr) 2008-09-29
IL132947A0 (en) 2001-03-19
KR20010013126A (ko) 2001-02-26
DE69829511T2 (de) 2006-02-16
RS20070459A (en) 2008-06-05
TNSN98074A1 (fr) 2005-03-15
US7745466B2 (en) 2010-06-29
AR059589A2 (es) 2008-04-16
ID29306A (id) 2001-08-16
HU225987B1 (en) 2008-02-28
SK284837B6 (sk) 2005-12-01
EG24291A (en) 2009-01-08
EE9900550A (et) 2000-06-15
NO317518B1 (no) 2004-11-08
LU91871I2 (fr) 2011-11-21
DE122012000017I1 (de) 2012-08-16
JP2007161734A (ja) 2007-06-28
RS50067B (sr) 2009-01-22
SI0984957T1 (en) 2003-10-31
SA98190280B1 (ar) 2006-07-04
MA26500A1 (fr) 2004-12-20
EP0984957B3 (en) 2013-09-18
PT1273581E (pt) 2005-06-30
RU2184115C2 (ru) 2002-06-27
CA2290963A1 (en) 1998-12-03
HU0001849D0 (tr) 2002-05-29
EP0984957A1 (en) 2000-03-15
LU92017I2 (fr) 2012-08-06
US20050075369A1 (en) 2005-04-07
PL337180A1 (en) 2000-08-14
US8466175B2 (en) 2013-06-18
US20080255363A1 (en) 2008-10-16
CN1161351C (zh) 2004-08-11
IS5272A (is) 1999-11-25
SE9702065L (sv) 1998-12-01
CA2521391A1 (en) 1998-12-03
ES2195345T3 (es) 2003-12-01
JP4002303B2 (ja) 2007-10-31
US8076361B2 (en) 2011-12-13
ATE239011T1 (de) 2003-05-15
CY2012029I2 (el) 2015-08-05
SI1273581T1 (tr) 2005-08-31
SK285137B6 (sk) 2006-07-07
YU60999A (sh) 2002-03-18
BR9809509A (pt) 2000-06-20
US20020198239A1 (en) 2002-12-26
CZ297585B6 (cs) 2007-01-10
CN1258295A (zh) 2000-06-28
MY127793A (en) 2006-12-29
DE69829511D1 (de) 2005-04-28
HRP980263A2 (en) 1999-02-28
WO1998054171A1 (en) 1998-12-03
NO2011010I1 (no) 2011-06-20
ATE291574T1 (de) 2005-04-15
EP1273581A1 (en) 2003-01-08
DE69814069T3 (de) 2014-03-27
AR012717A1 (es) 2000-11-08
HRP980263B1 (en) 2002-02-28
CA2290963C (en) 2006-03-28
JP2002501529A (ja) 2002-01-15
SA05260296B1 (ar) 2008-04-16
AU722839B2 (en) 2000-08-10
SK162599A3 (en) 2000-06-12
US7411070B2 (en) 2008-08-12
US20110130570A1 (en) 2011-06-02
NO2012011I1 (no) 2012-06-18
KR100527804B1 (ko) 2005-11-15
MEP18008A (en) 2010-10-10
IS2774B (is) 2012-03-15
US20120252847A1 (en) 2012-10-04

Similar Documents

Publication Publication Date Title
TR199902934T2 (tr) S-Omeprazolün yeni yapisi.
TR200102138T2 (tr) (S)-Omeprazolün potasyum tuzu.
TR200101282T2 (tr) Omeprozolün yeni kristalli formu
MY127871A (en) Omeprazole sodium salt
NO1995006I1 (no) Omeprazole/ 5-metoksy-2-[[(4-metoksy-3,5-dimetyl-2-pyridinyl)metyl]sulfinyl]-1H-benzimidazol
BR9508292A (pt) Processos para a sintese enãncio-seletiva de um composto,(-)-5-metóxi-2[[(4-metóxi-3,5-dimetil-2-piridinil) metil]sulfinil]-1h-benzimidazol,(+)-5-fluoro-2-(((4-ciclopropilmetóxi-2-piridinil) metil) sulfinil)-1h-benzimidazol,(-)-5-fluoro-2-(((4-ciclopropilmetóxi-2-piridinil) metil) sulfinil)-1h-benzimidazol,(-)-5-fluoro-2-(((4-ciclopropilmetóxi-2-piridinil) metil) sulfinil)-1h-benzimidazol,(-)-5-carbometóxi-6-metil-2-[[(3,4-dimetóxi-2-piridinil) metil] sulfinil]-1h-benzimidazol,(+)-5-carbometóxi-6-metil-2-[[(3,4-dimetóxi-2-piridinil) metil] sulfinil]-1h benzimidazol composto e uso dos compostos
MY111737A (en) Use of omeprazole as an antimicrobial agent.
MY125399A (en) Benzimidazole compound crystal.
ZA989999B (en) New process for the preparation of 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)1H-benzimidazole
DE60216273D1 (de) Kristalline form von omeprazol
MXPA05009183A (es) Polimorfos de s-omeprazol.
KR100463031B1 (ko) 5-메톡시-2-[3,5-디메틸-4-메톡시피리딜메틸)설피닐]-1h-벤즈이미다졸의신규제조방법
YU32301A (sh) Novi kristalni oblik omeprazola
MY118724A (en) New crystalline form of omeprazole